Skip to main content
S&P 5007,585.73-0.45%DOW52,093.11-0.63%NASDAQ25,981.57-0.78%BTC$75,934.00-1.36%ETH$2,406.06-2.96%GOLD$4,384.50+1.19%OIL$103.82-1.90%
Smart Investors Daily
TN

NASDAQ · TNXP

Tonix Pharmaceuticals Holding Corp.

Healthcare · Biotechnology

$11.62

Down-$0.11 (-0.94%)

Updated Sep 16, 2026, 12:02 PM

SID Score

3.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
172.07M
P/E ratio
-2.71
Dividend yield
0.00%
52-week range
$9.40 – $17.00
Volume
288.35K
Avg. volume
886.98K

Price performance

TNXP price history

1M range · 20 trading sessions · Daily adjusted prices

TNXP closed at $11.62 after 20 trading sessions, down 8.21% for the selected period.

Last close
$11.62
Period change
-8.21%
Period low
$11.62
Period high
$14.10
Daily close
View OHLC price history
TNXP OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 15, 2026$11.72$11.84$11.52$11.62288.35K
Sep 14, 2026$11.78$12.24$11.59$11.73454.68K
Sep 11, 2026$12.44$12.615$11.66$11.87513.43K
Sep 10, 2026$12.705$12.705$12.2189$12.28288.02K
Sep 9, 2026$13.09$13.12$12.80$12.83167.64K
Sep 8, 2026$13.15$13.48$12.57$13.16363.37K
Sep 4, 2026$13.30$13.33$12.99$13.14252.49K
Sep 3, 2026$13.49$13.60$13.21$13.37264.36K
Sep 2, 2026$14.00$14.015$13.37$13.38421.42K
Sep 1, 2026$13.92$14.12$13.395$13.98498.21K
Aug 31, 2026$13.68$14.50$13.35$14.10568.79K
Aug 28, 2026$13.52$13.98$13.295$13.59490.5K
Aug 27, 2026$13.66$14.05$13.445$13.56541.58K
Aug 26, 2026$13.55$13.9599$13.04$13.64514.03K
Aug 25, 2026$12.56$13.95$12.50$13.661.14M
Aug 24, 2026$12.89$12.90$12.25$12.45250K
Aug 21, 2026$12.57$12.82$12.52$12.55369.68K
Aug 20, 2026$12.66$12.79$12.3274$12.39360.53K
Aug 19, 2026$12.67$13.16$12.6264$12.73598.84K
Aug 18, 2026$12.41$12.83$12.2696$12.66188.43K

Latest TNXP news

The latest Smart Investors Daily articles mentioning TNXP.

Stock researchCompany · Overview

TNXP research

Overview

Company profile and research snapshot.

Company profile

Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
TNXP recent ratings
DateFirmRatingTarget
Jun 25, 2026Raymond JamesStrong Buy—
May 4, 2026TD CowenBuy—
Mar 20, 2025Noble Capital MarketsOutperform—
Jul 22, 2024Alliance Global PartnersBuy—
Feb 28, 2024Dawson JamesBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 8, 2026

Tonix Pharmaceuticals Promotes Thomas Englese, MBA, to Chief Commercial Officer

Mr. Englese’s leadership of Tonix’s commercial organization since 2024 has included the go-to-market strategy and U.S. launch of TONMYA®, with growth across sales, managed care, and patient accessBERKELEY HEIGHTS, N.J., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial-stage biopharmaceutical company, today announced the promotion of Thomas Englese to Chief Commercial Officer, effective immediately. Mr

Yahoo · Sep 2, 2026

TNXP: $11.0 Million in Tonmya® Net Revenue in 2Q26

By David Bautz, PhD NASDAQ: TNXP READ THE FULL TNXP RESEARCH REPORT Business Update $11.0 Million in Net Revenue for Tonmya® in 2Q26 Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) is continuing the commercial launch of Tonmya® following its approval in August 2025 and commercial launch in November 2025. Sales metrics for the second quarter of 2026 continue to show substantial growth in

Yahoo · Sep 2, 2026

Tonix Pharmaceuticals to Participate in Cantor’s 2026 Global Healthcare Conference

BERKELEY HEIGHTS, N.J., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial-stage biopharmaceutical company, today announced that the management team will participate in a fireside chat and 1x1s at Cantor’s 2026 Global Healthcare Conference, being held September 9-11, 2026, in New York. Cantor’s 2026 Global Healthcare ConferenceFireside ChatPresenter: Seth Lederman, M.D., President and Chief Executive Of

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By